CORONA REMEDIES Q2 FY27 CONCALL: MAINTAINS REVENUE GROWTH TARGET AT 1.5X INDIAN PHARMA MARKET; EXPECTS 20% PAT GROWTH, VOCADIN TARGETS 25% CAGR & FY27 EXPORT REVENUE GUIDANCE AT ₹60–65 CR